Patents by Inventor Marijke A. M. von der Mohlen

Marijke A. M. von der Mohlen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human therapeutic uses of BPI protein products
    Patent number: 6586400
    Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: July 1, 2003
    Assignee: Xoma Corporation
    Inventors: Nadav Friedmann, Patrick J. Scannon, Sander J. H. van Deventer, Marijke A. M. von der Mohlen, Nancy Wedel
  • Human therapeutic uses of BPI Protein products
    Publication number: 20020094952
    Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
    Type: Application
    Filed: December 8, 2000
    Publication date: July 18, 2002
    Applicant: XOMA Corporation
    Inventors: Nadav Friedmann, Patrick J. Scannon, Sander J.H. van Deventer, Marijke A.M. von der Mohlen, Nancy Wedel
  • Human therapeutic uses of BPI protein products
    Patent number: 6191112
    Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
    Type: Grant
    Filed: September 2, 1999
    Date of Patent: February 20, 2001
    Assignee: Xoma Corporation
    Inventors: Nadav Friedmann, Patrick J. Scannon, Sander J. H. van Deventer, Marijke A. M. von der Mohlen, Nancy Wedel
  • Human therapeutic uses of BPI protein products
    Patent number: 5952302
    Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
    Type: Grant
    Filed: May 18, 1998
    Date of Patent: September 14, 1999
    Assignee: Xoma Corporation
    Inventors: Nadav Friedmann, Patrick J. Scannon, Sander J.H. van Deventer, Marijke A.M. von der Mohlen, Nancy Wedel
  • Human therapeutic uses of BPI protein products
    Patent number: 5753620
    Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
    Type: Grant
    Filed: January 24, 1995
    Date of Patent: May 19, 1998
    Assignee: XOMA Corporation
    Inventors: Nadav Friedmann, Patrick J. Scannon, Sander J. H. van Deventer, Marijke A. M. von der Mohlen, Nancy Wedel
  • Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
    Patent number: 5643875
    Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
    Type: Grant
    Filed: August 16, 1994
    Date of Patent: July 1, 1997
    Inventors: Nadav Friedmann, Patrick J. Scannon, Sander J. H. van Deventer, Marijke A. M. von der Mohlen, Nancy Wedel